GlobeNewswire by notified

Notification on convocation of Annual General Meeting of Shareholders of Joint Stock Company “Latvijas Gāze”

Share

The Management Board of joint stock company “Latvijas Gāze”, registration number: 40003000642, legal address: Aristida Briana street 6, Riga, LV-1001, Latvia (hereinafter – the “Company”), hereby convenes and announces that the Annual General Meeting of Shareholders of the Company will take place on 19 June 2024 at 10:00 at Vagonu street 20, Riga, Latvia.

The agenda:

  1. Reports of the Board, the Council and the Audit Committee, and the certified auditor’s opinion of the joint stock company “Latvijas Gāze”, approval of the Annual Report 2023 of the joint stock company “Latvijas Gāze”.
  1. The coverage of losses for 2023 of the joint stock company “Latvijas Gāze”.
  1. Election of the auditor and setting of remuneration to the auditor of the joint stock company “Latvijas Gāze”.
  2. On determination of the renumeration for the previous Supervisory Council member of the joint stock company "Latvijas Gāze".
  3. On the exclusion of joint stock company "Latvijas Gāze" shares from the regulated market.
  4. On the share conversion of the joint stock company "Latvijas Gāze", on the new wording of the Articles of Association and on the selection of the central securities depository in which to register the shares of the joint stock company "Latvijas Gāze".

The Management Board of the Company will provide the shareholders with the possibility to vote before the meeting and to connect to the meeting remotely, without physical attendance.

The record date for shareholders’ participation at the Annual General Meeting of shareholders of the Company is 11 June 2024. Only the persons who are shareholders on the record date with the number of shares held by them on the record date are authorized to participate in the Annual General Meeting of shareholders of the Company on 19 June 2024 as well as to vote in writing before the shareholders' meeting.

Shareholders have a right to participate in the meeting (including filling and submitting the voting before the meeting) in person or by mediation of their legal representatives or authorized persons. If the shareholder is represented by the authorized person, the power of attorney should be attached to the voting or the application form but legal representatives should attach to the voting or the application form the document proofing representation rights.

The form of a written power of attorney is available on the website of the Company www.lg.lv page Shareholders Meetings, on website of the central storage of regulated information - csri.investinfo.lv and website of joint stock company “Nasdaq Riga” - www.nasdaqbaltic.com.

Voting prior to the meeting
Shareholders are invited to exercise their rights to vote in writing before the shareholders' meeting by sending a vote signed with a secure electronic signature to the e-mail: investor.relations@lg.lv or signed in paper form by post to the legal address of the Company at Aristida Briana street 6, Riga, LV-1001, Latvia.

The required voting form will be available on the website of the Company www.lg.lv page Shareholders Meetings, on website of the central storage of regulated information - csri.investinfo.lv and website of joint stock company “Nasdaq Riga” - www.nasdaqbaltic.com.  Such a vote will be considered if received by 18 June 2024 (including). The voting form will be published together with the draft resolutions of the meeting.

Shareholders who voted before the meeting will be considered present at the meeting. A shareholder who has voted before the shareholders' meeting may ask the Company to confirm the receipt of the vote. The Company shall send a confirmation to the shareholder immediately upon receipt of the shareholder's vote.

Participation and voting at the meeting
The registration and identification of shareholders will take place in the following order:

  1. The shareholder must send the application form signed with a secure electronic signature to the e-mail address: investor.relations@lg.lv or a signed in paper form by post to the legal address of the Company Aristida Briana street 6, Riga, LV-1001, Latvia, by 14 June 2024 at 17:00. If the shareholder wants to participate in the meeting remotely a copy of shareholder’s (or representative’s) identification document together with contacts (phone number and e-mail) should be attached to the application form in order to carry out identification of the shareholder.
  2. Shareholders applied for participation in the meeting remotely will receive an individual connection link to the meeting by indicated e-mail until 19 June 2024  at 9:00.
  3. Shareholders who have applied for participation in the meeting remotely using the link provided must join the meeting from 9:00 to 9:45 and be prepared to present a personal identification document to carry out the video identification.
  4. The video and audio streaming of the meeting and the video identification process could be recorded.
  5. The registration of shareholders who have applied for participation in the meeting in a presence will take place on the day of the shareholders’ meeting on 19 June 2024 from 9:00 to 9:45 at the meeting venue. Shareholders or their representatives should present passport or other identification document upon registration.

The shareholders representing at least one-twentieth of the company's share capital, have the right to request the Management Board to include additional points on the agenda of the meeting no later than by 4 June 2024 (including). Shareholders representing at least one-twentieth of the company's share capital have the right to submit draft decisions on the issues included in the agenda of the meeting no later than by 12 June 2024 (including). If a shareholder submits a written request to the Management Board no later than by 12 June 2024 (including), the Management Board will provide all the requested information on the issues included in the agenda no later than on 14 June 2024. All the above mentioned correspondence should be sent to the e-mail address: investor.relations@lg.lv signed with a safe electronic signature or by post to the legal address of the Company at Aristida Briana street 6, Riga, LV-1001, Latvia.

The draft new version of the Articles of Association of the Company, draft decisions and voting forms have been published together with this notice.

Information on the shareholders’ meeting is also available on the website of the Company www.lg.lv page Shareholders Meetings, on website of the central storage of regulated information - csri.investinfo.lv and website of joint stock company “Nasdaq Riga” - www.nasdaqbaltic.com.

The total amount of shares and the total amount of the shares with voting rights of the Company is 39 900 000.

Annexes:

  1. New wording of the Articles of Association
  2. The draft resolutions
  3. The voting form
  4. The Supervisory Council report
  5. The Audit Committee report
  6. The power of attorney form
  7. The application form for remote participation

The Board of the Joint Stock Company “Latvijas Gāze”

 About the JSC "Latvijas Gāze"

Founded in 1991, JSC "Latvijas Gāze" is one of the leaders of the Baltic energy sector and provides the wolesale and sale of natural gas to business customers in Latvia, Estonia and Finland. In the household segment, JSC "Latvijas Gāze" is the largest and most prominent natural gas trader in Latvia. The company has been listed on the NASDAQ Riga stock exchange since February 15, 1999 - a proof of high standards in terms of transparent governance, responsibility, and care for its customers, investors, and the society as a whole.


Additional information:
Sandra Joksta
Phone +371 67 374 369,
e-mail: investor.relations@lg.lv

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.21.5.2024 02:25:00 CEST | Press release

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ— Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis. “We are proud to make SIMLANDI available in the U.S. to patients and providers,” said Thomas Rainey, Senior Vice President, U.S. Market Access at Teva. “Biosimilars create opportunities for cost savings across the healthcare system, and SIMLANDI’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Hu

IDEX Biometrics – Number of shares in Tranche 1 vs Tranche 2 in the private placement on 15 May 202420.5.2024 23:52:54 CEST | Press release

Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the “Company”) on 15 May 2024 regarding a successful private placement of shares. By inadvertence, the announcement contained a slight error in the allocation of private placement shares between Tranche 1, as issued by the Board pursuant to an authorization to issue shares granted by the extraordinary general meeting dated 21 December 2023, and Tranche 2, to be issued subject to approval by an extraordinary general meeting to be called and scheduled for on or about 12 June 2024. The correct number of Tranche 1 shares is 27,940,213, and the correct number of Tranche 2 shares is 5,393,120, each having a par value of NOK 0.15, with a subscription price of NOK 1.65 per share in the private placement. Consequently, following the issuance of Tranche 1 shares, the Company's share capital is increased with NOK 4,191,031.95 from NOK 42,018,983.25 to NOK 46,210,015.20, and the Company will have 308,066,768 shares issued

INVNT™ ANNOUNCED AS SPONSOR AND CO-PRODUCER OF DISCOVERY STAGE AT SXSW SYDNEY® 202420.5.2024 23:00:00 CEST | Press release

Also named as an endorsed Creative Experiential Partner for the 2024 event Sydney, May 20, 2024 (GLOBE NEWSWIRE) -- INVNT™, the Experiential Disrupter Agency, has today been announced as the sponsor and co-producer of the SXSW Sydney 2024 Discovery Stage after a successful collaboration at last year’s inaugural event. For the second consecutive year, INVNT will bring its world-class expertise in production and innovative brand storytelling and “Challenge Everything” ethos to SXSW Sydney, where it will continue its legacy of hosting, curating and presenting the Discovery Stage and activating across the event’s key pillars of Tech & Innovation, Music, Games and Screen. Featured within the SXSW Sydney Tech & Innovation Expo, the 2024 Discovery Stage will play host to inspiring innovation leaders who are redefining industry norms and will be a place to explore the latest developments in technology and meet startup founders who are poised to disrupt the status quo. As last year’s Discovery

Nokia Corporation: Repurchase of own shares on 20.05.202420.5.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 20 May 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 20.05.2024 Espoo, Finland – On 20 May 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL370,3933.56CEUX--BATE--AQEU--TQEX--Total370,3933.56 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of tra

Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM20.5.2024 20:15:00 CEST | Press release

Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammationData support the potential of Dupixent as the first new treatment approach in more than a decadeand first-ever targeted therapy for COPD Paris and Tarrytown, N.Y. May 20, 2024. Late-breaking data were presented from the NOTUS phase 3 study evaluating the investigational use of Dupixent® (dupilumab) as an add-on maintenance treatment in adults with uncontrolled COPD on maximal standard-of-care inhaled therapy (nearly all on triple therapy) and evidence of type 2 inflammation (i.e., blood eosinophils ≥300 cells per μL). The NOTUS study confirmed the positive results demonstrated in the landmark phase 3 BOREAS s

HiddenA line styled icon from Orion Icon Library.Eye